

Medical Cannabis Laws and Opioid Analgesic Overdose 1999-2010

JAMA Internal Medicine

174, 1668

DOI: [10.1001/jamainternmed.2014.4005](https://doi.org/10.1001/jamainternmed.2014.4005)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Statesâ€™ implementation of the Affordable Care Act and the supply of physicians waived to prescribe buprenorphine for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2015, 157, 36-43.	1.6	31
2	Use of Prescription Pain Medications Among Medical Cannabis Patients: Comparisons of Pain Levels, Functioning, and Patterns of Alcohol and Other Drug Use. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 406-413.	0.6	23
3	The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 644-654.	0.6	65
4	Are medical marijuana users different from recreational users? The view from primary care. <i>American Journal on Addictions</i> , 2015, 24, 599-606.	1.3	82
5	A safer alternative: Cannabis substitution as harm reduction. <i>Drug and Alcohol Review</i> , 2015, 34, 654-659.	1.1	115
6	Medicinal Marijuana. <i>Clinical Journal of Pain</i> , 2015, 31, 931-932.	0.8	4
7	Anderson et al. Respond. <i>American Journal of Public Health</i> , 2015, 105, e8-e9.	1.5	1
8	Correlates of Opioid Use in Adults With Self-Reported Drug Use Recruited From Public Safety-Net Primary Care Clinics. <i>Journal of Addiction Medicine</i> , 2015, 9, 417-426.	1.4	11
9	Medical cannabis: time for clear thinking. <i>Medical Journal of Australia</i> , 2015, 202, 74-75.	0.8	6
10	Medicinal cannabis. <i>Australian Prescriber</i> , 2015, 38, 212-215.	0.5	26
11	Prescribing medical cannabis in Canada: Are we being too cautious?. <i>Canadian Journal of Public Health</i> , 2015, 106, e328-e330.	1.1	15
12	The Kids Aren't Alright, But Older Adults Are: How Medical Marijuana Market Growth Impacts Adult and Adolescent Substance-Related Outcomes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	16
13	The Impact of Legalizing and Regulating Weed: Issues with Study Design and Emerging Findings in the USA. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 34, 173-198.	0.8	25
14	Drug policy, values and the public health approach â€“four lessons from drug policy reform movements. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2015, 32, 347-364.	0.7	12
15	Medical marijuana programs â€” Why might they matter for public health and why should we better understand their impacts?. <i>Preventive Medicine Reports</i> , 2015, 2, 53-56.	0.8	20
16	Re-branding cannabis: the next generation of chronic pain medicine?. <i>Pain Management</i> , 2015, 5, 13-21.	0.7	31
17	Pot in Palliative Care: What We Need to Know. <i>Journal of Palliative Medicine</i> , 2015, 18, 7-10.	0.6	8
18	Assessing the public health impacts of legalizing recreational cannabis use in the USA. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 607-615.	2.3	141

#	ARTICLE	IF	CITATIONS
19	Nonopioid Medications for Pain. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2015, 26, 219-248.	0.7	27
20	The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. <i>Journal of Health Economics</i> , 2015, 42, 64-80.	1.3	304
21	Examining the relationship between marijuana use, medical marijuana dispensaries, and abusive and neglectful parenting. <i>Child Abuse and Neglect</i> , 2015, 48, 170-178.	1.3	42
22	The rise of marijuana and the fall of cocaine in the <scp>United States</scp>: for better, for worse?. <i>Addiction</i> , 2015, 110, 737-738.	1.7	2
23	What Ecologic Analyses Cannot Tell Us About Medical Marijuana Legalization and Opioid Pain Medication Mortality. <i>JAMA Internal Medicine</i> , 2015, 175, 655.	2.6	29
24	Experiences of Kratom Users: A Qualitative Analysis. <i>Journal of Psychoactive Drugs</i> , 2015, 47, 360-367.	1.0	110
25	Cannabinoid modulation of drug reward and the implications of marijuana legalization. <i>Brain Research</i> , 2015, 1628, 233-243.	1.1	69
26	An Overview of Major and Minor Phytocannabinoids. , 2016, , 672-678.		11
27	Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. <i>Frontiers in Pharmacology</i> , 2016, 7, 309.	1.6	97
28	A Userâ€™s Guide to Cannabinoid Therapies in Oncology. <i>Current Oncology</i> , 2016, 23, 398-406.	0.9	60
29	Evaluating the public health impacts of legalizing recreational cannabis use in the United States. <i>Addiction</i> , 2016, 111, 1764-1773.	1.7	270
30	Medical marijuana and pain management. <i>Disease-a-Month</i> , 2016, 62, 346-352.	0.4	17
31	Opioid Overdose Deaths and Floridaâ€™s Crackdown on Pill Mills. <i>American Journal of Public Health</i> , 2016, 106, 291-297.	1.5	90
32	Cannabinoids in Medical Practice. <i>Alternative and Complementary Therapies</i> , 2016, 22, 59-63.	0.1	6
33	Gaps in medical marijuana policy implementation: Real-time perspectives from marijuana dispensary entrepreneurs, health care professionals and medical marijuana patients. <i>Drugs: Education, Prevention and Policy</i> , 2016, 23, 422-434.	0.8	13
34	Overview on Prevalence and Recent Trends in Adolescent Substance Use and Abuse. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2016, 25, 349-365.	1.0	38
35	Medical Marijuana and Crime. <i>Journal of Drug Issues</i> , 2016, 46, 122-134.	0.6	24
36	Assessing and Treating Co-occurring Substance Abuse. , 2016, , 215-230.		0

#	ARTICLE	IF	CITATIONS
38	Clinical applications of hallucinogens: A review.. Experimental and Clinical Psychopharmacology, 2016, 24, 229-268.	1.3	130
39	How does state marijuana policy affect US youth? Medical marijuana laws, marijuana use and perceived harmfulness: 1991â€“2014. Addiction, 2016, 111, 2187-2195.	1.7	130
40	Frequency, predictors, and outcomes of urine drug testing among patients with advanced cancer on chronic opioid therapy at an outpatient supportive care clinic. Cancer, 2016, 122, 3732-3739.	2.0	49
41	Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Haematologica, 2016, 101, 566-577.	1.7	51
42	Medical marijuana legalization and cigarette and marijuana co-use in adolescents and adults. Drug and Alcohol Dependence, 2016, 166, 32-38.	1.6	65
43	State Medical Marijuana Laws and the Prevalence of Opioids Detected Among Fatally Injured Drivers. American Journal of Public Health, 2016, 106, 2032-2037.	1.5	82
44	Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates. Health Affairs, 2016, 35, 1324-1332.	2.5	250
45	US states that allow medical marijuana see drop in prescriptions for other drugs, study finds. BMJ, The, 2016, 354, i3942.	3.0	2
46	The costs of prohibition. American Journal of Drug and Alcohol Abuse, 2016, 42, 621-623.	1.1	7
47	A Public Health of Consequence: Review of the November 2016 Issue ofAJPH. American Journal of Public Health, 2016, 106, 1901-1902.	1.5	0
48	National and Northern New England Opioid Prescribing Patterns, 2013â€“2014. Pain Medicine, 2016, 18, pnw231.	0.9	3
49	Molecular Pharmacology of CB1 and CB2 Cannabinoid Receptors. , 2016, , 713-721.		6
50	Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 2016, 35, 326-333.	1.1	124
51	State Legal Restrictions and Prescription-Opioid Use among Disabled Adults. New England Journal of Medicine, 2016, 375, 44-53.	13.9	208
52	Capturing Heterogeneity in Medical Marijuana Policies: A Taxonomy of Regulatory Regimes Across the United States. Substance Use and Misuse, 2016, 51, 1174-1184.	0.7	48
53	A Changing Environment: 2016 NCSBN Environmental Scan. Journal of Nursing Regulation, 2016, 6, 4-37.	1.6	12
54	Medical Marijuana in Patients Prescribed Opioids. Mayo Clinic Proceedings, 2016, 91, 830-832.	1.4	7
55	Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. Digestive Diseases and Sciences, 2016, 61, 1844-1852.	1.1	25

#	ARTICLE	IF	CITATIONS
56	Drug poisoning deaths in the United States, 1999â€”2012: a statistical adjustment analysis. <i>Population Health Metrics</i> , 2016, 14, 2.	1.3	42
57	Nonmedical prescription pain reliever and alcohol consumption among cannabis users. <i>Drug and Alcohol Dependence</i> , 2016, 159, 101-108.	1.6	16
58	Supervised Controlled Substance Use. <i>American Journal of Bioethics</i> , 2016, 16, 56-58.	0.5	1
59	Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy. <i>Supportive Care in Cancer</i> , 2016, 24, 3517-3524.	1.0	24
60	Public health and international drug policy. <i>Lancet, The</i> , 2016, 387, 1427-1480.	6.3	460
61	Comparative policy analysis for alcohol and drugs: Current state of the field. <i>International Journal of Drug Policy</i> , 2016, 31, 39-50.	1.6	32
62	Cannabinoids in Medical Practice. <i>Cannabis and Cannabinoid Research</i> , 2016, 1, 38-43.	1.5	6
63	Colorado Cannabis Legalization and Its Effect on Emergency Care. <i>Annals of Emergency Medicine</i> , 2016, 68, 71-75.	0.3	79
64	Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates Than Newer â€œMedicalizedâ€™ Programs. <i>Health Affairs</i> , 2016, 35, 480-488.	2.5	82
65	Cannabis in Pain Treatment: Clinical and Research Considerations. <i>Journal of Pain</i> , 2016, 17, 654-668.	0.7	85
66	Public health benefits from legalizing cannabis: both sides of the coin. <i>Cmaj</i> , 2016, 188, 63.2-63.	0.9	2
67	Marijuana Legalization: Impact on Physicians and Public Health. <i>Annual Review of Medicine</i> , 2016, 67, 453-466.	5.0	147
68	Theory and methods in comparative drug and alcohol policy research: Response to a review of the literature. <i>International Journal of Drug Policy</i> , 2017, 41, 126-131.	1.6	16
69	The association of psychedelic use and opioid use disorders among illicit users in the United States. <i>Journal of Psychopharmacology</i> , 2017, 31, 606-613.	2.0	49
70	Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. <i>Drug and Alcohol Dependence</i> , 2017, 173, 144-150.	1.6	145
71	Cannabinoids in treatment-resistant epilepsy: A review. <i>Epilepsy and Behavior</i> , 2017, 70, 341-348.	0.9	161
72	Public perceptions of arguments supporting and opposing recreational marijuana legalization. <i>Preventive Medicine</i> , 2017, 99, 80-86.	1.6	86
73	Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. <i>Journal of Psychopharmacology</i> , 2017, 31, 569-575.	2.0	151

#	ARTICLE	IF	CITATIONS
74	Chronic pain patients' perspectives of medical cannabis. <i>Pain</i> , 2017, 158, 1373-1379.	2.0	75
75	The Health Shadow Price and Economically Meaningful Threshold Values. , 2017, , 255-278.		1
76	Cannabinoids in Palliative Medicine. <i>Journal of Palliative Medicine</i> , 2017, 20, 692-694.	0.6	1
77	Medical Marijuana and Marijuana Legalization. <i>Annual Review of Clinical Psychology</i> , 2017, 13, 397-419.	6.3	201
78	Cannabis and Pain: A Clinical Review. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 96-104.	1.5	172
79	Marijuana and acute health care contacts in Colorado. <i>Preventive Medicine</i> , 2017, 104, 24-30.	1.6	63
80	Medical cannabis use among patients with chronic pain in an interdisciplinary pain rehabilitation program: Characterization and treatment outcomes. <i>Journal of Substance Abuse Treatment</i> , 2017, 77, 95-100.	1.5	20
81	Cannabis for Pain and Headaches: Primer. <i>Current Pain and Headache Reports</i> , 2017, 21, 19.	1.3	15
82	Higher Prescription Opioid Dose is Associated With Worse Patient-Reported Pain Outcomes and More Health Care Utilization. <i>Journal of Pain</i> , 2017, 18, 437-445.	0.7	63
83	Substance Use, Health, and Functioning Characteristics of Medical Marijuana Program Participants Compared to the General Adult Population in Ontario (Canada). <i>Journal of Psychoactive Drugs</i> , 2017, 49, 31-38.	1.0	10
84	Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards. <i>Journal of Occupational and Environmental Medicine</i> , 2017, 59, 1114-1126.	0.9	38
85	Recreational Cannabis Legalization and Opioid-Related Deaths in Colorado, 2000â€“2015. <i>American Journal of Public Health</i> , 2017, 107, 1827-1829.	1.5	106
86	How Medical Marijuana Smoothed the Transition to Marijuana Legalization in the United States. <i>Annual Review of Law and Social Science</i> , 2017, 13, 181-202.	0.8	57
87	Commentary on Pardo (2017) and Moyo <i>et al.</i> (2017): Much still unknown about prescription drug monitoring programs. <i>Addiction</i> , 2017, 112, 1797-1798.	1.7	8
88	Cessation of Injecting and Preceding Drug Use Patterns Among a Prospective Cohort of Street-Involved Youth. <i>Journal of Adolescent Health</i> , 2017, 61, 612-618.	1.2	9
89	Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. <i>Drug and Alcohol Dependence</i> , 2017, 173, S55-S64.	1.6	34
90	Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. <i>Addiction</i> , 2017, 112, 2206-2216.	1.7	75
91	Comparing Policies Across US Drug Markets. , 2017, , 181-190.		0

#	ARTICLE	IF	CITATIONS
92	Icelandâ€™s Peculiar Beer Ban, 1915â€“1989. , 2017, , 237-248.		0
93	Medicinal cannabis. Nursing, 2017, 47, 40-46.	0.2	5
94	Commentary: Navigating the complexities of marijuana. Preventive Medicine, 2017, 104, 10-12.	1.6	3
95	Two steps forward, one step back: current harm reduction policy and politics in the United States. Harm Reduction Journal, 2017, 14, 37.	1.3	48
96	Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. Cannabis and Cannabinoid Research, 2017, 2, 160-166.	1.5	183
97	Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. International Journal of Drug Policy, 2017, 47, 1-8.	1.6	36
98	Clearing the haze: the complexities and challenges of research on state marijuana laws. Annals of the New York Academy of Sciences, 2017, 1394, 55-73.	1.8	31
99	Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review, 2017, 51, 15-29.	6.0	168
100	The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002â€“2014. Drug and Alcohol Dependence, 2017, 170, 51-58.	1.6	137
101	Fatal Overdoses of Opioids in Israel 2005â€“2014. European Addiction Research, 2017, 23, 276-283.	1.3	17
102	The Canadian Medical Association should support a medical access stream for cannabis. Cmaj, 2017, 189, E1565-E1565.	0.9	1
103	The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada. PLoS ONE, 2017, 12, e0187633.	1.1	32
104	Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduction Journal, 2017, 14, 58.	1.3	71
105	Recent legalization of cannabis use: effects on sleep, health, and workplace safety. Nature and Science of Sleep, 2017, Volume 9, 249-251.	1.4	15
106	Recent advances in understanding and managing cancer pain. F1000Research, 2017, 6, 945.	0.8	72
107	The Effects of Medical Marijuana Laws on Prescribed Opioids and Other Prescription Drugs. SSRN Electronic Journal, 0, , .	0.4	9
108	Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 705-713.	1.8	59
109	Cannabis: A Review of the Good and the Bad. Topics in Pain Management, 2018, 33, 1-6.	0.1	1

#	ARTICLE	IF	CITATIONS
110	It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. <i>Addiction</i> , 2018, 113, 987-988.	1.7	37
111	Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 153-156.	1.0	4
112	Medical Marijuana Users are More Likely to Use Prescription Drugs Medically and Nonmedically. <i>Journal of Addiction Medicine</i> , 2018, 12, 295-299.	1.4	64
113	Willingness to Participate in Longitudinal Research Among People with Chronic Pain Who Take Medical Cannabis: A Cross-Sectional Survey. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 45-53.	1.5	6
114	Cannabis for Chronic Pain: Challenges and Considerations. <i>Pharmacotherapy</i> , 2018, 38, 651-662.	1.2	75
115	Do medical marijuana laws reduce addictions and deaths related to pain killers?. <i>Journal of Health Economics</i> , 2018, 58, 29-42.	1.3	248
116	Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system. <i>Preventive Medicine</i> , 2018, 110, 31-37.	1.6	48
117	Cannabis Use is Associated with Lower Odds of Prescription Opioid Analgesic Use Among HIV-Infected Individuals with Chronic Pain. <i>Substance Use and Misuse</i> , 2018, 53, 1602-1607.	0.7	43
118	Is recovery from cannabis use problems different from alcohol and other drugs? Results from a national probability-based sample of the United States adult population. <i>International Journal of Drug Policy</i> , 2018, 53, 55-64.	1.6	11
119	Associations between medical cannabis and other drug use among unstably housed women. <i>International Journal of Drug Policy</i> , 2018, 52, 45-51.	1.6	8
120	Perceptions of the relative harmfulness of marijuana and alcohol among adults in Oregon. <i>Preventive Medicine</i> , 2018, 109, 34-38.	1.6	3
121	Practical considerations in medical cannabis administration and dosing. <i>European Journal of Internal Medicine</i> , 2018, 49, 12-19.	1.0	423
122	Does Medical Cannabis Reduce Use of Prescription Opioids?. <i>American Journal of Psychiatry</i> , 2018, 175, 6-7.	4.0	6
123	Designing Difference in Difference Studies: Best Practices for Public Health Policy Research. <i>Annual Review of Public Health</i> , 2018, 39, 453-469.	7.6	857
124	Factors Associated With County-Level Differences in U.S. Drug-Related Mortality Rates. <i>American Journal of Preventive Medicine</i> , 2018, 54, 611-619.	1.6	138
125	The Role of Cannabis Legalization in the Opioid Crisis. <i>JAMA Internal Medicine</i> , 2018, 178, 679.	2.6	16
126	Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. <i>JAMA Internal Medicine</i> , 2018, 178, 667.	2.6	191
127	Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees. <i>JAMA Internal Medicine</i> , 2018, 178, 673.	2.6	175

#	ARTICLE	IF	CITATIONS
128	Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts. <i>Pain Medicine</i> , 2018, 19, 793-807.	0.9	77
129	The effect of state laws designed to prevent nonmedical prescription opioid use on overdose deaths and treatment. <i>Health Economics (United Kingdom)</i> , 2018, 27, 294-305.	0.8	29
130	The use of cannabis in response to the opioid crisis: A review of the literature. <i>Nursing Outlook</i> , 2018, 66, 56-65.	1.5	70
131	Cannabis use moderates the relationship between pain and negative affect in adults with opioid use disorder. <i>Addictive Behaviors</i> , 2018, 77, 225-231.	1.7	25
132	Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complementary, and Tapering Uses. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 146-153.	2.1	33
133	Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States. <i>American Journal of Psychiatry</i> , 2018, 175, 47-53.	4.0	195
134	US Epidemiology of Cannabis Use and Associated Problems. <i>Neuropsychopharmacology</i> , 2018, 43, 195-212.	2.8	425
135	Patient Perceptions of the Use of Medical Marijuana in the Treatment of Pain After Musculoskeletal Trauma: A Survey of Patients at 2 Trauma Centers in Massachusetts. <i>Journal of Orthopaedic Trauma</i> , 2018, 32, e25-e30.	0.7	29
136	Medical marijuana in pediatric oncology: A review of the evidence and implications for practice. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26826.	0.8	26
137	Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 59-64.e1.	1.2	39
138	Therapeutic Benefit of Smoked Cannabis in Randomized Placebo-Controlled Studies. <i>Pharmacotherapy</i> , 2018, 38, 80-85.	1.2	17
139	Examining the relationship between medical cannabis laws and cardiovascular deaths in the US. <i>International Journal of Drug Policy</i> , 2018, 53, 1-7.	1.6	29
140	Medical marijuana laws and adolescent use of marijuana and other substances: Alcohol, cigarettes, prescription drugs, and other illicit drugs. <i>Drug and Alcohol Dependence</i> , 2018, 183, 62-68.	1.6	88
141	Kratom use and mental health: A systematic review. <i>Drug and Alcohol Dependence</i> , 2018, 183, 134-140.	1.6	104
142	Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio. <i>European Journal of Pharmacology</i> , 2018, 819, 217-224.	1.7	26
143	Could cannabis liberalisation lead to wider changes in drug policies and outcomes?. <i>International Journal of Drug Policy</i> , 2018, 51, 156-159.	1.6	17
144	Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD. <i>American Journal of Kidney Diseases</i> , 2018, 71, 267-274.	2.1	25
145	The Case For. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 475-477.	0.5	0

#	ARTICLE	IF	CITATIONS
146	Medical Oncologists' Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1957-1962.	0.8	150
147	Care After Chemotherapy: Peripheral Neuropathy, Cannabis for Symptom Control, and Mindfulness. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 469-479.	1.8	9
148	Ethics at the Intersection of Chronic Pain and Substance Use. <i>Developments in Neuroethics and Bioethics</i> , 2018, 1, 127-150.	0.6	4
149	Cannabinoids in chronic pain management: a skein to be untangled. <i>Minerva Anestesiologica</i> , 2018, 84, 893-895.	0.6	2
150	Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 259-271.	1.5	52
152	The Impact of Cannabis Access Laws on Opioid Prescribing. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
155	Self-Reported Marijuana Use Is Associated with Increased Use of Prescription Opioids Following Traumatic Musculoskeletal Injury. <i>Journal of Bone and Joint Surgery - Series A</i> , 2018, 100, 2095-2102.	1.4	41
156	The Effect of Medical Cannabis Dispensaries on Opioid and Heroin Overdose Mortality. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
157	Should Medical Cannabis Administered by Inhalation Be Allowed for Hospitalized Patients?. <i>Canadian Journal of Hospital Pharmacy</i> , 2018, 71, .	0.1	1
158	What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. <i>International Review of Psychiatry</i> , 2018, 30, 91-106.	1.4	25
159	Medical Cannabis. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1842-1847.	1.4	79
160	Adolescents and Perceived Riskiness of Marijuana: Why Care?. <i>Journal of Adolescent Health</i> , 2018, 63, 377-378.	1.2	8
161	The opioid epidemic in the United States—Overview, origins, and potential solutions. <i>Cancer</i> , 2018, 124, 4279-4286.	2.0	20
162	The Politics of Passing and Implementing Medical Marijuana in Ohio. <i>SSRN Electronic Journal</i> , 2018, , .	0.4	1
163	High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. <i>Addiction</i> , 2018, 113, 2250-2258.	1.7	48
164	Maternal Cannabis Use During a Child's Lifetime Associated With Earlier Initiation. <i>American Journal of Preventive Medicine</i> , 2018, 55, 592-602.	1.6	15
165	Risk Factors for Opioid Overdose. <i>Current Treatment Options in Psychiatry</i> , 2018, 5, 323-333.	0.7	4
167	Marijuana use by middle-aged and older adults in the United States, 2015–2016. <i>Drug and Alcohol Dependence</i> , 2018, 191, 374-381.	1.6	82

#	ARTICLE	IF	CITATIONS
168	Emerging Evidence for Cannabis' Role in Opioid Use Disorder. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 179-189.	1.5	116
169	Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs. <i>Drug and Alcohol Dependence</i> , 2018, 192, 112-117.	1.6	3
170	Opioid Death Rate Acceleration in Jurisdictions Legalizing Marijuana Use—Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 1281.	2.6	0
171	High times: The effect of medical marijuana laws on student time use. <i>Economics of Education Review</i> , 2018, 66, 142-153.	0.7	11
172	Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. <i>Headache</i> , 2018, 58, 1139-1186.	1.8	161
173	Medical Cannabis and Pain Management: How Might the Role of Cannabis Be Defined in Pain Medicine?. <i>Journal of Applied Laboratory Medicine</i> , The, 2018, 2, 485-488.	0.6	1
174	Opioid prescriptions decreased in US states where marijuana was legally accessible. <i>BMJ: British Medical Journal</i> , 0, , k1514.	2.4	1
175	Cannabis medicinal: una guía para enfermeras. <i>Nursing (Ed Española)</i> , 2018, 35, 34-39.	0.0	0
176	Part I: Current Legislation, Scientific Literature Review, and Nursing Implications. <i>Journal of Nursing Regulation</i> , 2018, 9, S6-S21.	1.6	1
177	Racial/Ethnic Disparities in Arrests for Drug Possession After California Proposition 47, 2011–2016. <i>American Journal of Public Health</i> , 2018, 108, 987-993.	1.5	21
178	Accuracy of Patient Opioid Use Reporting at the Time of Medical Cannabis License Renewal. <i>Pain Research and Management</i> , 2018, 2018, 1-4.	0.7	3
179	Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. <i>International Review of Psychiatry</i> , 2018, 30, 251-267.	1.4	52
180	The role of cannabinoids in pain control: the good, the bad, and the ugly. <i>Minerva Anestesiologica</i> , 2018, 84, 955-969.	0.6	21
181	We Can't Go Cold Turkey: Why Suppressing Drug Markets Endangers Society. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 325-342.	0.4	6
182	Medical marijuana laws and workplace fatalities in the United States. <i>International Journal of Drug Policy</i> , 2018, 60, 33-39.	1.6	37
183	Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis. <i>Frontiers in Psychiatry</i> , 2018, 9, 283.	1.3	14
184	Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. <i>Mental Health Clinician</i> , 2018, 8, 110-115.	0.5	35
185	The case for medical cannabis—an essay by M P Barnes. <i>BMJ: British Medical Journal</i> , 2018, , k3230.	2.4	4

#	ARTICLE	IF	CITATIONS
186	Perinatal Marijuana Use and the Developing Child. JAMA - Journal of the American Medical Association, 2018, 320, 545.	3.8	38
187	Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction, 2018, 113, 2060-2070.	1.7	69
188	Marijuana Use in Adults Living with Sickle Cell Disease. Cannabis and Cannabinoid Research, 2018, 3, 162-165.	1.5	24
189	The Association Between Cannabis Use and Aberrant Behaviors During Chronic Opioid Therapy for Chronic Pain. Pain Medicine, 2018, 19, 1997-2008.	0.9	21
190	Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. Journal of Headache and Pain, 2018, 19, 37.	2.5	126
191	Cannabis and the Opioid Crisis. Cannabis and Cannabinoid Research, 2018, 3, 108-116.	1.5	10
192	New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program. Cannabis and Cannabinoid Research, 2018, 3, 74-84.	1.5	59
193	Marijuana and Prescription Pain Reliever Use among Cigarette Smokers. Journal of Psychoactive Drugs, 2018, 50, 339-347.	1.0	0
194	Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology, 2018, 235, 2357-2365.	1.5	20
195	Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients. Laryngoscope Investigative Otolaryngology, 2018, 3, 169-177.	0.6	8
196	Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an "index" for monitoring and evaluation. Journal of Public Health, 2019, 41, 412-421.	1.0	50
197	Orthopaedic surgery patients who use recreational marijuana have less pre-operative pain. International Orthopaedics, 2019, 43, 283-292.	0.9	24
198	Exploring cannabis use reasons and experiences among mobile cannabis delivery patients. Journal of Substance Use, 2019, 24, 15-20.	0.3	5
199	Opportunities for cannabis in supportive care in cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986636.	1.4	61
200	Disagreement and Uncertainty Among Experts About how to Respond to Marijuana Use in Patients on Long-term Opioids for Chronic Pain: Results of a Delphi Study. Pain Medicine, 2020, 21, 247-254.	0.9	6
201	Prescription drug monitoring programs: Assessing the association between "best practices" and opioid use in Medicare. Health Services Research, 2019, 54, 1045-1054.	1.0	9
202	Do Î²-adrenoreceptor blocking drugs associate with reduced risk of symptomatic osteoarthritis and total joint replacement in the general population? A primary care-based, prospective cohort study using the Clinical Practice Research Datalink. BMJ Open, 2019, 9, e032050.	0.8	3
203	Emerging Public Health Law and Policy Issues Concerning State Medical Cannabis Programs. Journal of Law, Medicine and Ethics, 2019, 47, 108-111.	0.4	3

#	ARTICLE	IF	CITATIONS
204	Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2019, 202, 33-38.	1.6	9
205	Medical and non-medical cannabis use and risk of prescription opioid use disorder: Findings from propensity score matching. <i>Drug and Alcohol Review</i> , 2019, 38, 597-605.	1.1	18
206	The effectiveness of self-directed medical cannabis treatment for pain. <i>Complementary Therapies in Medicine</i> , 2019, 46, 123-130.	1.3	37
207	Prescription drug monitoring programs operational characteristics and fatal heroin poisoning. <i>International Journal of Drug Policy</i> , 2019, 74, 174-180.	1.6	44
208	Medical cannabis: A new frontier for pharmacists. <i>Pharmacy Today</i> , 2019, 25, 42-53.	0.0	1
209	Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 644-663.	1.1	180
210	The effect of cannabis laws on opioid use. <i>International Journal of Drug Policy</i> , 2019, 74, 152-159.	1.6	19
211	Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 422-452.	1.3	39
212	The Impact of Medical Marijuana Laws and Dispensaries on Self-Reported Health. <i>Forum for Health Economics and Policy</i> , 2019, 22, .	0.2	8
213	Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 606-621.	1.1	21
214	Not in my backyard? Not so fast. The effect of marijuana legalization on neighborhood crime. <i>Regional Science and Urban Economics</i> , 2019, 78, 103460.	1.4	31
215	Medical Cannabis Policy: Considerations for Older Patients and Their Health-Care Providers. <i>The Public Policy and Aging Report</i> , 2019, 29, 106-110.	0.8	0
216	State marijuana laws and opioid overdose mortality. <i>Injury Epidemiology</i> , 2019, 6, 38.	0.8	33
217	Legalized Cannabis in Colorado Emergency Departments: A Cautionary Review of Negative Health and Safety Effects. <i>Western Journal of Emergency Medicine</i> , 2019, 20, 557-572.	0.6	42
218	The Interaction of Alcohol Use and Cannabis Use Problems in Relation to Opioid Misuse Among Adults with Chronic Pain. <i>International Journal of Behavioral Medicine</i> , 2019, 26, 569-575.	0.8	10
219	Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. <i>International Journal of Drug Policy</i> , 2019, 73, 96-99.	1.6	3
220	Does fiscal decentralization affect regional disparities in health? Quasi-experimental evidence from Italy. <i>Regional Science and Urban Economics</i> , 2019, 78, 103465.	1.4	31
221	The Associations of Neighborhood Availability of Marijuana Dispensaries and DATA-2000 Waivered Providers with Hospital Stays Related to Opioids. <i>Substance Use and Misuse</i> , 2019, 54, 2387-2399.	0.7	5

#	ARTICLE	IF	CITATIONS
222	Perspectives on cannabis as a substitute for opioid analgesics. <i>Pain Management</i> , 2019, 9, 191-203.	0.7	30
223	Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. <i>Cancers</i> , 2019, 11, 129.	1.7	26
224	Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use, and High-risk Opioid Use. <i>Journal of General Internal Medicine</i> , 2019, 34, 1419-1426.	1.3	46
225	Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain. <i>Journal of Pain</i> , 2019, 20, 830-841.	0.7	82
226	A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety. <i>Current Oncology Reports</i> , 2019, 21, 10.	1.8	31
227	Drivers of the fatal drug epidemic. <i>Journal of Health Economics</i> , 2019, 64, 25-42.	1.3	128
228	Qualifying Conditions Of Medical Cannabis License Holders In The United States. <i>Health Affairs</i> , 2019, 38, 295-302.	2.5	139
229	Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 527-537.	1.1	14
230	Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. <i>Psychopharmacology</i> , 2019, 236, 3341-3352.	1.5	21
231	Association between medical cannabis laws and opioid overdose mortality has reversed over time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12624-12626.	3.3	154
232	A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 506-513.	1.1	15
233	Should Oncologists Recommend Cannabis?. <i>Current Treatment Options in Oncology</i> , 2019, 20, 59.	1.3	20
234	Marijuana as a Substitute for Prescription Medications: A Qualitative Study. <i>Substance Use and Misuse</i> , 2019, 54, 1894-1902.	0.7	23
235	Crossing the Line: Care of a Pediatric Patient with Intractable Seizures and Severe Neuropathic Pain in Absence of Access to Medical Marijuana. <i>Journal of Palliative Medicine</i> , 2019, 22, 1232-1235.	0.6	0
236	Access to medical marijuana does not reduce opioid overdoses in US, study finds. <i>BMJ: British Medical Journal</i> , 2019, 365, l4188.	2.4	1
237	Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain. <i>Journal of Pain</i> , 2019, 20, 1362-1372.	0.7	56
238	The Implementation of Marijuana Legalization in New York. <i>Psychiatric Services</i> , 2019, 70, 625-628.	1.1	1
239	Dronabinol use in France between 2004 and 2017. <i>Revue Neurologique</i> , 2019, 175, 298-304.	0.6	4

#	ARTICLE	IF	CITATIONS
240	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	1.6	113
241	Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose. <i>JAMA Internal Medicine</i> , 2019, 179, 805.	2.6	165
242	Why Insurance Companies Should Pay for Medical Cannabis. <i>American Journal of Bioethics</i> , 2019, 19, 8-10.	0.5	4
243	Using Cannabis to Treat Cancer-Related Pain. <i>Seminars in Oncology Nursing</i> , 2019, 35, 300-309.	0.7	14
244	Cannabinoids in Pain Treatment: An Overview. <i>Pain Management Nursing</i> , 2019, 20, 107-112.	0.4	8
245	A Review of Cannabis in Chronic Kidney Disease Symptom Management. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811982839.	0.6	31
246	Î”9-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions. <i>Neuropharmacology</i> , 2019, 151, 127-135.	2.0	49
247	Qualitative Analysis of Cannabis Use Among Older Adults in Colorado. <i>Drugs and Aging</i> , 2019, 36, 655-666.	1.3	46
248	The Role of Cannabidiol in Palliative Care #370. <i>Journal of Palliative Medicine</i> , 2019, 22, 337-338.	0.6	2
249	Self-management strategies amongst Australian women with endometriosis: a national online survey. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 17.	3.7	94
250	Good Samaritan harm reduction policy and drug overdose deaths. <i>Health Services Research</i> , 2019, 54, 407-416.	1.0	19
251	The Effect of Medical Marijuana Laws on the Health and Labor Supply of Older Adults: Evidence from the Health and Retirement Study. <i>Journal of Policy Analysis and Management</i> , 2019, 38, 455-480.	1.1	33
252	Medical marijuana, not miracle marijuana: some wellâ€publicized studies about medical marijuana do not pass a reality check. <i>Addiction</i> , 2019, 114, 1128-1129.	1.7	8
253	Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e027495.	0.8	25
254	Molecular Mechanism and Cannabinoid Pharmacology. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 323-353.	0.9	39
255	Necessity of addressing motivations for cannabis use to guide research. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 547-550.	1.1	1
256	Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. <i>PLoS Medicine</i> , 2019, 16, e1002967.	3.9	56
257	Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. <i>CMAJ Open</i> , 2019, 7, E665-E673.	1.1	20

#	ARTICLE	IF	CITATIONS
258	Clinical Trials for Opioid Use Disorder. Handbook of Experimental Pharmacology, 2019, 258, 167-202.	0.9	3
259	Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 195-201.	0.9	9
260	CORR Insights®: Has Self-reported Marijuana Use Changed in Patients Undergoing Total Joint Arthroplasty After the Legalization of Marijuana?. Clinical Orthopaedics and Related Research, 2019, 477, 101-103.	0.7	4
261	Cannabinoids: a new approach for pain control?. Current Opinion in Oncology, 2019, 31, 275-279.	1.1	11
262	Addressing the context and consequences of substance use, misuse, and dependence: A global imperative. PLoS Medicine, 2019, 16, e1003000.	3.9	8
263	Trends in Opioid Misuse among Marijuana Users and Non-Users in the U.S. from 2007â€“2017. International Journal of Environmental Research and Public Health, 2019, 16, 4585.	1.2	5
264	What Have Been the Public Health Impacts of Cannabis Legalisation in the USA? A Review of Evidence on Adverse and Beneficial Effects. Current Addiction Reports, 2019, 6, 418-428.	1.6	29
265	Prescription Drug Monitoring Programs and Opioid Overdoses. Epidemiology, 2019, 30, 212-220.	1.2	28
266	Reduced urinary opioid levels from pain management patients associated with marijuana use. Pain Management, 2019, 9, 441-447.	0.7	2
267	Priming primary care providers to engage in evidence-based discussions about cannabis with patients. Addiction Science & Clinical Practice, 2019, 14, 42.	1.2	10
268	Driving Under the Influence of Cannabis: A Framework for Future Policy. Anesthesia and Analgesia, 2019, 128, 1300-1308.	1.1	14
269	Opioid and Cannabis Co-Use among Adults With Chronic Pain: Relations to Substance Misuse, Mental Health, and Pain Experience. Journal of Addiction Medicine, 2019, 13, 287-294.	1.4	41
270	Barriers to Achieving Optimal Success with Medical Cannabis: Opportunities for Quality Improvement. Journal of Alternative and Complementary Medicine, 2019, 25, 5-7.	2.1	10
271	Associations of state-level rates of depression and fatal opioid overdose in the United States, 2011â€“2015. Social Psychiatry and Psychiatric Epidemiology, 2019, 54, 131-134.	1.6	10
272	Applying Best Practice Guidelines on Chronic Pain in Clinical Practiceâ€”Treating Patients Who Suffer From Pain and Addiction. , 2019, , 137-156.		1
273	Medical Cannabis in the Skilled Nursing Facility: A Novel Approach to Improving Symptom Management and Quality of Life. Journal of the American Medical Directors Association, 2019, 20, 94-98.	1.2	15
274	Cannabis Legalization Does Not Influence Patient Compliance with Opioid Therapy. American Journal of Medicine, 2019, 132, 347-353.	0.6	9
275	Patientsâ€™ and cliniciansâ€™ perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. International Journal of Drug Policy, 2019, 63, 23-28.	1.6	37

#	ARTICLE	IF	CITATIONS
276	Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 135-144.	1.8	33
277	Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse. <i>Journal of Policy Analysis and Management</i> , 2019, 38, 181-209.	1.1	96
278	Recreational marijuana legalization and prescription opioids received by Medicaid enrollees. <i>Drug and Alcohol Dependence</i> , 2019, 194, 13-19.	1.6	50
279	Pain And Opioid Systems, Implications In The Opioid Epidemic. <i>Current Opinion in Behavioral Sciences</i> , 2019, 26, 69-74.	2.0	7
280	Prevention and Treatment of Opioid Misuse and Addiction. <i>JAMA Psychiatry</i> , 2019, 76, 208.	6.0	388
281	Impact of Medical Marijuana Laws on State-Level Marijuana Use by Age and Gender, 2004-2013. <i>Prevention Science</i> , 2019, 20, 205-214.	1.5	74
282	Accuracy of Medical Marijuana Claims Made by Popular Websites. <i>Journal of Pharmacy Practice</i> , 2020, 33, 457-464.	0.5	10
283	Tetrahydrocannabinol - "friend or foe?" Debate. <i>Clinical Toxicology</i> , 2020, 58, 75-81.	0.8	3
284	THE CROSS-BORDER SPILLOVER EFFECTS OF RECREATIONAL MARIJUANA LEGALIZATION. <i>Economic Inquiry</i> , 2020, 58, 642-666.	1.0	40
285	Medical cannabis for chronic pain: can it make a difference in pain management?. <i>Journal of Anesthesia</i> , 2020, 34, 95-103.	0.7	29
286	THE EFFECTS OF RECREATIONAL MARIJUANA LEGALIZATION AND DISPENSING ON OPIOID MORTALITY. <i>Economic Inquiry</i> , 2020, 58, 589-606.	1.0	57
287	THE EFFECTS OF MEDICAL MARIJUANA DISPENSARIES ON ADVERSE OPIOID OUTCOMES. <i>Economic Inquiry</i> , 2020, 58, 569-588.	1.0	30
288	Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction. <i>Pain Management Nursing</i> , 2020, 21, 43-47.	0.4	15
289	Cannabis for Chronic Pain: We Simply Don't Know. <i>Pain Medicine</i> , 2020, 21, 1091-1092.	0.9	2
290	Reducing the risks of distortion in cannabis research. <i>Addiction</i> , 2020, 115, 799-801.	1.7	4
291	Clinician Knowledge, Attitudes, and Practice Regarding Cannabis: Results from a National Veterans Health Administration Survey. <i>Pain Medicine</i> , 2020, 21, 3180-3186.	0.9	24
292	Cannabinoids. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 769-788.	1.1	1
293	The impact of cannabis access laws on opioid prescribing. <i>Journal of Health Economics</i> , 2020, 69, 102273.	1.3	44

#	ARTICLE	IF	CITATIONS
294	The role of the endogenous neurotransmitters associated with neuropathic pain and in the opioid crisis: The innate pain-relieving system. <i>Brain Research Bulletin</i> , 2020, 155, 129-136.	1.4	22
295	Characteristics of Dispensary Patients that Limit Alcohol after Initiating Cannabis. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 145-152.	1.0	1
296	Changes in alcohol and cigarette consumption in response to medical and recreational cannabis legalization: Evidence from U.S. state tax receipt data. <i>International Journal of Drug Policy</i> , 2020, 75, 102585.	1.6	26
297	Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses. <i>Epidemiology</i> , 2020, 31, 32-42.	1.2	40
298	Change in Pain Status and Subsequent Opioid and Marijuana Use Among Long-Term Adult Survivors of Childhood Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa070.	1.4	1
299	Pain management in patients with chronic kidney disease and end-stage kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 671-680.	1.0	25
300	Examining the effects of legalizing marijuana in Colorado and Washington on clearance rates: a quasi-experimental design. <i>Journal of Experimental Criminology</i> , 2022, 18, 365-386.	1.9	8
301	Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs. <i>Journal of Health Economics</i> , 2020, 74, 102371.	1.3	15
302	State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events. <i>Medical Care</i> , 2020, 58, 610-616.	1.1	8
303	Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 812-822.	1.1	4
304	The Role of Cannabis in Orthopedic Surgery. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2360-2367.	0.3	3
305	Cannabinoids and Pain. , 2020, , 70-85.		0
306	Cannabis as a Gateway Drug for Opioid Use Disorder. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 268-274.	0.4	24
307	The emergence of innovative cannabis distribution projects in the downtown eastside of Vancouver, Canada. <i>International Journal of Drug Policy</i> , 2020, 79, 102737.	1.6	17
308	Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3902.	1.0	6
309	Trajectories of cannabis use and risk for opioid misuse in a young adult urban cohort. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108182.	1.6	12
310	Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 255-262.	1.5	14
311	Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease. <i>JAMA Network Open</i> , 2020, 3, e2010874.	2.8	37

#	ARTICLE	IF	CITATIONS
312	<p>Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions</p>. Adolescent Health, Medicine and Therapeutics, 2020, Volume 11, 53-61.	0.7	6
313	A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018. Public Health Reports, 2020, 135, 100S-127S.	1.3	24
314	Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review. BMJ Open, 2020, 10, e035148.	0.8	28
315	Association of State Policies Allowing Medical Cannabis for Opioid Use Disorder With Dispensary Marketing for This Indication. JAMA Network Open, 2020, 3, e2010001.	2.8	16
316	Daring discourse â€“ no: cannabinoids should not be used for acute postoperative pain management. Regional Anesthesia and Pain Medicine, 2020, 45, 520-523.	1.1	1
317	Marijuana users are likely to report opioid misuse among adults over 50 years in representative sample of the United States (2002â€“2014). Journal of Addictive Diseases, 2020, 39, 66-73.	0.8	6
318	Medical Cannabis: A New <i>Old</i> Tool for Palliative Care. Journal of Alternative and Complementary Medicine, 2020, 26, 778-780.	2.1	1
319	Opioid Misuse and the Availability of Medical Marijuana Through Dispensaries. Journal of Studies on Alcohol and Drugs, 2020, 81, 489-496.	0.6	4
320	Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances, 2020, 4, 3814-3821.	2.5	7
321	Is Medical Marijuana Legalization Associated With Prescription Drug Misuse, Illicit Drug Use, or Combination of Both Among Adults in the United States?. Journal of Drug Issues, 2020, 50, 566-578.	0.6	7
322	In our war against the opioid epidemic, could â€“weedâ€™™ be a winner?. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 423-429.	0.7	2
323	Illicit Cannabis Usage as a Management Strategy in New Zealand Women with Endometriosis: An Online Survey. Journal of Women's Health, 2021, 30, 1485-1492.	1.5	18
324	The relationship of opioid prescriptions and the educational performance of children. Social Science and Medicine, 2020, 265, 113406.	1.8	3
325	The effectiveness of inhaled Cannabis flower for the treatment of agitation/irritability, anxiety, and common stress. Journal of Cannabis Research, 2020, 2, 47.	1.5	10
326	Cannabinoid-Based Medication. , 2020, , 137-163.		0
327	Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports, 2020, 34, 100667.	0.3	8
328	Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado. International Journal of Environmental Research and Public Health, 2020, 17, 3251.	1.2	15
329	Use and Perceptions of Opioids Versus Marijuana among Cancer Survivors. Journal of Cancer Education, 2022, 37, 91-101.	0.6	4

#	ARTICLE	IF	CITATIONS
330	Opioid use disorders and hospital palliative care among patients with gastrointestinal cancers. <i>Medicine (United States)</i> , 2020, 99, e20723.	0.4	4
331	Exploring the effect of Colorado's recreational marijuana policy on opioid overdose rates. <i>Public Health</i> , 2020, 185, 8-14.	1.4	12
332	A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 548-558.	1.5	23
333	A lottery test of the effect of dispensaries on emergency room visits in Arizona. <i>Health Economics (United Kingdom)</i> , 2020, 29, 854-864.	0.8	10
334	Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study. <i>Pain Medicine</i> , 2020, 21, 3073-3086.	0.9	32
335	The Role of the Cannabinoid System in Pain Control: Basic and Clinical Implications. <i>Current Pain and Headache Reports</i> , 2020, 24, 35.	1.3	9
336	Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds. <i>International Journal of Drug Policy</i> , 2020, 77, 102711.	1.6	6
337	Green Hope: Perspectives on Cannabis from People who Use Opioids. <i>Sociological Inquiry</i> , 2021, 91, 668-695.	1.4	3
338	Association of Medicaid Expansion With Opioid Overdose Mortality in the United States. <i>JAMA Network Open</i> , 2020, 3, e1919066.	2.8	65
339	Is marijuana use associated with decreased use of prescription opioids? Toxicological findings from two US national samples of drivers. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 12.	1.0	11
340	U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001â€“2002 and 2012â€“2013. <i>American Journal of Psychiatry</i> , 2020, 177, 611-618.	4.0	30
341	The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 263-270.	1.5	36
342	The nephrologist's guide to cannabis and cannabinoids. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 248-257.	1.0	31
343	Opioids and Cannabinoids for Osteoarthritis: Either, Both, or Neither. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 29-44.	0.6	0
344	Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). <i>PLoS ONE</i> , 2020, 15, e0227966.	1.1	133
345	The Void in Clinician Counseling of Cannabis Use. <i>Journal of General Internal Medicine</i> , 2020, 35, 1875-1878.	1.3	7
346	Cannabis and the Developing Adolescent Brain. <i>Current Treatment Options in Psychiatry</i> , 2020, 7, 144-161.	0.7	20
347	Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence. <i>European Neuropsychopharmacology</i> , 2020, 36, 206-216.	0.3	19

#	ARTICLE	IF	CITATIONS
348	The Effect of Marijuana Legalization on the Trajectories of Hard Drug-Related Hospitalizations: A Growth Curve Analysis of the County-Level State Inpatient Database in Washington, 2009-2015. <i>Journal of Drug Issues</i> , 2020, 50, 273-285.	0.6	9
349	Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks. <i>Journal of Psychopharmacology</i> , 2020, 34, 654-662.	2.0	12
350	Shared Decision-Making for Patients Using Cannabis for Pain Symptom Management in the United States. <i>Pain Management Nursing</i> , 2021, 22, 15-20.	0.4	4
351	Is Cannabis being used as a substitute for non-medical opioids by adults with problem substance use in the United States? A within-person analysis. <i>Addiction</i> , 2021, 116, 1113-1121.	1.7	25
352	Methodological challenges and proposed solutions for evaluating opioid policy effectiveness. <i>Health Services and Outcomes Research Methodology</i> , 2021, 21, 21-41.	0.8	21
353	Perioperative Cannabis as a Potential Solution for Reducing Opioid and Benzodiazepine Dependence. <i>JAMA Surgery</i> , 2021, 156, 181.	2.2	18
354	Can policy affect initiation of addictive substance use? Evidence from opioid prescribing. <i>Journal of Health Economics</i> , 2021, 76, 102397.	1.3	37
355	Opioid-sparing effects of cannabinoids: Myth or reality?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110065.	2.5	12
356	Cannabis use is associated with reduced risk of exposure to fentanyl among people on opioid agonist therapy during a community-wide overdose crisis. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108420.	1.6	14
357	Prevalence and Correlates of Cannabis Use in Massachusetts after Cannabis Legalization and before Retail Sales. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 158-167.	1.0	4
358	Factors associated with health-related cannabis use intentions among a community sample of people who inject drugs in Los Angeles and San Francisco, CA 2016 to 2018. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108421.	1.6	4
359	Cannabis Policy and Use. , 2021, , .		0
360	Medical Marijuana Laws, Marijuana Use, and Opioid-Related Outcomes among Women in the United States. <i>Women's Health Issues</i> , 2021, 31, 24-30.	0.9	5
361	Cannabis in Pain. , 2021, , 151-162.		1
362	Pharmacological Treatment of Fibromyalgia. , 2021, , 33-52.		3
363	Cannabis liberalisation and the US opioid crisis. <i>BMJ, The</i> , 2021, 372, n163.	3.0	4
364	Cannabinoids Future Research. , 2021, , 325-332.		0
365	Protocol: mixed-methods study of how implementation of US state medical cannabis laws affects treatment of chronic non-cancer pain and adverse opioid outcomes. <i>Implementation Science</i> , 2021, 16, 2.	2.5	5

#	ARTICLE	IF	CITATIONS
366	The associations of medical marijuana policies with opioid-related health care utilization. <i>Health Services Research</i> , 2021, 56, 299-309.	1.0	10
367	Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 537-544.	1.0	6
368	Opioid Mortality Following Implementation of Medical Cannabis Programs in the United States. <i>Pharmacopsychiatry</i> , 2021, 54, 91-95.	1.7	15
369	The prospective association between illicit drug use and nonprescription opioid use among vulnerable adolescents. <i>Preventive Medicine</i> , 2021, 143, 106383.	1.6	2
371	The impact of medical and recreational marijuana laws on opioid prescribing in employer-sponsored health insurance. <i>Health Economics (United Kingdom)</i> , 2021, 30, 989-1000.	0.8	15
372	Impact of Marijuana Legalization on Opioid Utilization in Patients Diagnosed with Pain. <i>Journal of General Internal Medicine</i> , 2021, 36, 3417-3422.	1.3	3
373	State Medical Cannabis Laws Associated With Reduction in Opioid Prescriptions by Orthopaedic Surgeons in Medicare Part D Cohort. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2021, 29, e188-e197.	1.1	19
374	Cannabis Use and Nonfatal Opioid Overdose among Patients Enrolled in Methadone Maintenance Treatment. <i>Substance Use and Misuse</i> , 2021, 56, 697-703.	0.7	0
375	Demand curve analysis of marijuana use among persons living with HIV. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108524.	1.6	4
376	The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review. <i>Current Neuropharmacology</i> , 2021, 19, 402-432.	1.4	10
377	Association between marijuana use and nonmedical prescription opioid use in the United States: are we shifting from one epidemic to another?. <i>Journal of Public Health Policy</i> , 2021, 42, 310-321.	1.0	0
378	Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. <i>Neuropsychopharmacology</i> , 2021, 46, 1451-1459.	2.8	17
379	Evolving Global Perspectives of Pharmacists: Dispensing Medical Cannabis. <i>Cannabis and Cannabinoid Research</i> , 2021, , .	1.5	0
380	Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain. <i>Frontiers in Pharmacology</i> , 2021, 12, 633168.	1.6	20
381	Use of Cannabis for Harm Reduction Among People at High Risk for Overdose in Vancouver, Canada (2016-2018). <i>American Journal of Public Health</i> , 2021, 111, 969-972.	1.5	29
383	Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State. <i>JAMA Network Open</i> , 2021, 4, e219375.	2.8	18
384	Illegal drug market responses to state recreational cannabis laws. <i>Addiction</i> , 2021, 116, 3433-3443.	1.7	10
385	Can cannabinoids still play a role as pain medications?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2293-2295.	0.9	0

#	ARTICLE	IF	CITATIONS
386	Delivering therapeutic cannabinoids via skin: Current state and future perspectives. <i>Journal of Controlled Release</i> , 2021, 334, 427-451.	4.8	35
387	Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. <i>BMJ Open</i> , 2021, 11, e047717.	0.8	51
388	Cannabis and pain: a scoping review. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2022, 72, 142-151.	0.2	7
389	New momentum in exploring marijuana's medical benefits. <i>Cancer Cytopathology</i> , 2021, 129, 575-576.	1.4	0
390	How medical are states'™ medical cannabis policies?: Proposing a standardized scale. <i>International Journal of Drug Policy</i> , 2021, 94, 103202.	1.6	16
391	A Scoping Review of Data Sources for the Conduct of Policy-Relevant Substance Use Research. <i>Public Health Reports</i> , 2022, 137, 944-954.	1.3	4
392	Marijuana liberalization policies and perinatal health. <i>Journal of Health Economics</i> , 2021, 80, 102537.	1.3	9
393	Possible opioid-sparing effect of cannabis-based medicine using individual-based data from the Norwegian Prescription Database. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, . .	1.2	1
394	Opioid and healthcare service use in medical cannabis patients with chronic pain: a prospective study. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e464-e468.	0.8	2
395	The State of the Evidence on the Association Between State Cannabis Laws and Opioid-Related Outcomes: a Review. <i>Current Addiction Reports</i> , 2021, 8, 538-545.	1.6	6
396	Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use. <i>American Journal of Preventive Medicine</i> , 2021, 61, 537-544.	1.6	5
397	Association between fatal opioid overdose and state medical cannabis laws in US national survey data, 2000-2011. <i>International Journal of Drug Policy</i> , 2022, 99, 103449.	1.6	9
398	Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study. <i>BMJ, The</i> , 2021, 372, m4957.	3.0	25
399	Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence. , 2021, , 223-230.		0
400	Prescription drug monitoring programs, opioid abuse, and crime. <i>Southern Economic Journal</i> , 2021, 87, 808-848.	1.3	18
401	Cannabinoids and orthopedic surgery: a systematic review of therapeutic studies. <i>Journal of Orthopaedic Surgery and Research</i> , 2021, 16, 57.	0.9	11
402	Medical marijuana and workers' compensation claiming. <i>Health Economics (United Kingdom)</i> , 2020, 29, 419-434.	0.8	20
403	Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study. <i>Pain Medicine</i> , 2021, 22, 727-739.	0.9	45

#	ARTICLE	IF	CITATIONS
404	Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?. <i>Journal of Addiction Medicine</i> , 2021, 15, 91-92.	1.4	11
405	Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain. <i>Obstetrics and Gynecology</i> , 2021, 137, 91-99.	1.2	9
406	Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2020, Publish Ahead of Print, S110-S116.	2.0	10
409	Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain. <i>BMJ Open</i> , 2020, 10, e043400.	0.8	9
410	Characteristics of Individuals with Spinal Cord Injury Who Use Cannabis for Therapeutic Purposes. <i>Topics in Spinal Cord Injury Rehabilitation</i> , 2016, 22, 3-12.	0.8	17
411	Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. <i>PLoS ONE</i> , 2017, 12, e0187795.	1.1	101
412	Characterizing motivations for cannabis use in a cohort of people who use illicit drugs: A latent class analysis. <i>PLoS ONE</i> , 2020, 15, e0233463.	1.1	25
413	Evidence shows that cannabis has fewer relative harms than opioids. <i>Cmaj</i> , 2020, 192, E166-E167.	0.9	5
414	The Challenges of Projecting the Public Health Impacts of Marijuana Legalization in Canada Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts". <i>International Journal of Health Policy and Management</i> , 2017, 6, 285-287.	0.5	11
415	Is There Less Opioid Abuse in States Where Marijuana Has Been Decriminalized, Either for Medicinal or Recreational Use? A Clin-IQ. <i>Journal of Patient-centered Research and Reviews</i> , 2019, 6, 267-273.	0.6	13
416	The Current Evidence for Marijuana as Medical Treatment. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 2096-2105.	1.4	4
417	Is medical marijuana legalisation possible in Poland?. <i>Central European Journal of Public Health</i> , 2018, 26, 45-48.	0.4	3
418	Time Trends Matter: The Case of Medical Cannabis Laws and Opioid Overdose Mortality. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
419	Spillover Effects of the Opioid Epidemic on Consumer Finance. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
420	Do-it-Yourself Medicine? The Impact of Light Cannabis Liberalization on Prescription Drugs. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
421	Opioid Prescriptions and the Educational Performance of Children. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
422	Navigating Blind in the Green Rush: Clinical Considerations and Harm Reduction Practices for Cannabis. <i>Current Drug Research Reviews</i> , 2019, 11, 3-11.	0.7	9
423	Characteristics of Marijuana Use Among Orthopedic Patients. <i>Orthopedics</i> , 2020, 43, 108-112.	0.5	4

#	ARTICLE	IF	CITATIONS
424	Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified. <i>Journal of Opioid Management</i> , 2018, 14, 295-303.	0.2	3
425	The Public Health Concerns of Marijuana Legalization: An Overview of Current Trends. <i>Cureus</i> , 2019, 11, e5806.	0.2	27
426	The Impact of Medical Marijuana Legalization on Opioid Prescriptions. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
427	Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11072.	1.2	2
429	Policy Implications and Applications Across Health and Aged Care Reform with Baby Boomer Ageing - from Age and Dementia Friendly Communities to Palliative Care. , 2017, , 279-320.		1
431	Medicaid, Marijuana and Opioids: Identifying Shocks to Opioid Mortality. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
432	Recent Analytical Approaches in Quality Control of Cannabis sativa L. and Its Preparations. <i>Records of Pharmaceutical and Biomedical Sciences</i> , 2018, 2, 10-22.	0.1	2
433	Unintended Consequences of Recreational and Medical Marijuana Laws On Adult and Youth Drug Use. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
434	Cannabinoids in Opioid Addiction Treatment: Pharmacological Mechanisms. , 2019, 07, .		1
435	Jagged little pills. <i>Faculty Dental Journal</i> , 2019, 10, 38-39.	0.0	0
436	Confronting Cannabis: Legalization on Native Nation Lands and the Impacts of Differential Federal Enforcement. <i>American Indian Quarterly</i> , 2019, 43, 408.	0.6	2
438	Uso medicinal de cannabis: una revisión de la evidencia. <i>Terapia Psicológica</i> , 2019, 37, 166-180.	0.2	2
440	Pain and Cannabis Markets. , 2020, , 77-106.		0
441	The North American Opioid Epidemic. , 2020, , 45-75.		0
443	Local Policy and Programmatic Activity to Address the US Opioid Crisis. <i>Journal of Public Health Management and Practice</i> , 2020, Publish Ahead of Print, 342-351.	0.7	1
444	Estudio de registro de pacientes con desórdenes del movimiento con autoprescripción de formas no estandarizadas de cannabis. Experiencia de un centro especializado en movimientos anormales de Buenos Aires. <i>Neurología Argentina</i> , 2020, 12, 165-171.	0.1	0
445	Cannabis (Marijuana) and Cannabinoids. , 2020, , 470-483.e5.		1
446	Lessons from Realm of Caring Foundation. , 2020, , 207-230.		0

#	ARTICLE	IF	CITATIONS
447	Association of medical cannabis licensure with prescription opioid receipt: A population-based, individual-level retrospective cohort study. <i>International Journal of Drug Policy</i> , 2022, 100, 103502.	1.6	2
448	Cannabinoids in Neurologic Conditions. , 2020, , 231-312.		0
449	Looking at Marijuana Through the Lens of Public Health. , 2020, , 453-491.		1
450	Medical Marijuana Laws and Labor Market Outcomes: Estimates Using a Border Discontinuity Design. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
452	Estratgia de patenteamento de derivados de Cannabis sativa para obteno da anuncia prvia da ANVISA. <i>Revista Fitos</i> , 2020, 14, 56-66.	0.0	0
453	Real World Evidence in Medical Cannabis Research. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 8-14.	0.8	38
455	Frequent Cannabis Use Is Negatively Associated with Frequency of Injection Drug Use Among People Who Inject Drugs in a Canadian Setting. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 435-445.	1.5	3
457	Cannabis for medical and scientific purposes: the Colombian landscape. <i>Colombian Journal of Anesthesiology</i> , 2021, 49, .	0.5	1
459	Why Marijuana Will Not Fix the Opioid Epidemic. <i>Missouri Medicine</i> , 2018, 115, 191-193.	0.3	7
461	Cannabis industry and medical cannabis clinics need regulation. <i>Canadian Family Physician</i> , 2019, 65, 864-868.	0.1	2
462	Medical Marijuana Policy Reform Reaches Florida: A Scoping Review. , 2019, 16, 128-136.		0
463	Clinical Approaches to Cannabis. <i>Medical Clinics of North America</i> , 2022, 106, 131-152.	1.1	5
464	Heterogeneous health effects of medical marijuana legalization: Evidence from young adults in the United States. <i>Health Economics (United Kingdom)</i> , 2021, , .	0.8	1
465	Medical and Non-Medical Opioid Use at the Intersection of Gender and Sexual Identity: Associations with State Medical Cannabis Law Status in a U.S. National Sample of Adults. <i>Archives of Sexual Behavior</i> , 2021, 50, 3551-3561.	1.2	2
466	Recreational Marijuana Laws and the Use of Opioids: Evidence from Nsduh Microdata. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
467	What do we know about opportunities and challenges for localities from Cannabis legalization?. <i>Review of Policy Research</i> , 2022, 39, 143-169.	2.8	16
469	Societal Costs and Outcomes of Medical and Recreational Marijuana Policies in the United States: A Systematic Review. <i>Medical Care Research and Review</i> , 2022, 79, 743-771.	1.0	5
470	Chronic pain and medical cannabis: Narrative review and practice considerations in persons living with HIV. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 342-353.	0.5	2

#	ARTICLE	IF	CITATIONS
471	Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. <i>Journal of Clinical Medicine</i> , 2022, 11, 558.	1.0	7
472	Responding to the opioid crisis in North America and beyond: recommendations of the Stanfordâ€”Lancet Commission. <i>Lancet, The</i> , 2022, 399, 555-604.	6.3	180
473	Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. <i>American Journal of Psychiatry</i> , 2022, 179, 98-109.	4.0	42
474	â€œI got a bunch of weed to help me through the withdrawalsâ€” Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. <i>PLoS ONE</i> , 2022, 17, e0263583.	1.1	14
475	Marijuana Legalization and Opioid Deaths. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
476	High-Speed Rail Development and Regional Inequalities: Evidence From Japan. <i>Transportation Research Record</i> , 2022, 2676, 363-378.	1.0	4
477	Marijuana Policy Bundles in the American States Over Time and Their Impact on the Use of Marijuana and Other Drugs. <i>Evaluation Review</i> , 2022, 46, 165-199.	0.4	2
478	Understanding Kratom Use: A Guide for Healthcare Providers. <i>Frontiers in Pharmacology</i> , 2022, 13, 801855.	1.6	30
479	Therapeutic Cannabis Use in Kidney Disease: A Survey of Canadian Nephrologists. <i>Kidney Medicine</i> , 2022, 4, 100453.	1.0	3
480	APCDs can Provide Important Insights for Surveilling the Opioid Epidemic, With Caveats. <i>Medical Care Research and Review</i> , 2022, 79, 594-601.	1.0	3
481	Drug-Drug Interaction Between Orally Administered Hydrocodone-Acetaminophen and Inhalation of Cannabis Smoke: A Case Report. <i>Hospital Pharmacy</i> , 0, , 001857872110613.	0.4	3
482	Cannabis Use for Endometriosis: Clinical and Legal Challenges in Australia and New Zealand. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 464-472.	1.5	6
483	Legal Status of Recreational Cannabis and Self-Reported Substitution of Cannabis for Opioids or Prescription Pain Medication in Canada and the United States. <i>Substance Abuse</i> , 2022, 43, 943-948.	1.1	4
484	Recreational cannabis legalizations associated with reductions in prescription drug utilization among Medicaid enrollees. <i>Health Economics (United Kingdom)</i> , 2022, , .	0.8	3
485	United States marijuana legalization and opioid mortality epidemic during 2010â€”2020 and pandemic implications. <i>Journal of the National Medical Association</i> , 2022, 114, 412-425.	0.6	2
486	Postmortem <sc>THC</sc> in decedents following legalization of recreational cannabis in Clark County, Nevada. <i>Journal of Forensic Sciences</i> , 2022, , .	0.9	0
487	Hand Surgery Patient Perspectives on Medical Cannabis: A Survey of Over 600 Patients. <i>Journal of Hand Surgery Global Online</i> , 2022, , .	0.3	1
488	Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance Use. <i>Cannabis and Cannabinoid Research</i> , 2022, , .	1.5	2

#	ARTICLE	IF	CITATIONS
489	Cannabis, cannabinoids, and cannabis-based medicines: future research directions for analgesia. <i>Regional Anesthesia and Pain Medicine</i> , 2022, 47, 437-444.	1.1	4
490	Opioid Distribution Trends in California Following Recreational Cannabis Legalization. <i>The Guthrie Journal of the Donald Guthrie Foundation for Medical Research</i> , 2022, 74, .	0.1	0
491	Do We Have Structure, Process and Outcomes to Support Cannabis as Supportive Therapy in Cancer?. <i>American Journal of Hospice and Palliative Medicine</i> , 2022, , 104990912211015.	0.8	2
492	Use of Cannabis Does Not Decrease Opioid Consumption in Patients Who Underwent Total Joint Arthroplasty. <i>Arthroplasty Today</i> , 2022, 15, 141-146.	0.8	7
493	Use of Cannabis as a Harm Reduction Strategy Among People Who Use Drugs: A Cohort Study. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 670-678.	1.5	8
494	Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol. <i>BMJ Open</i> , 2022, 12, e064457.	0.8	2
495	Making a joint decision: Cannabis as a potential substitute for opioids in obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 85, 59-67.	1.4	2
496	Real-time monitoring of cannabis and prescription opioid co-use patterns, analgesic effectiveness, and the opioid-sparing effect of cannabis in individuals with chronic pain. <i>Journal of Pain</i> , 2022, , .	0.7	1
497	Cannabinoids for Pain Modulation in Orthopedic Surgery. <i>Orthopedics</i> , 0, , 1-8.	0.5	0
498	Cannabis Use Disorder. , 2023, , 73-84.		0
499	Michigan Marijuana Legalization: Correlations Among Cannabis Use, Mental Health, and Other Factors. <i>Cureus</i> , 2022, , .	0.2	0
500	Self-Reported Cannabis Use Is Associated With a Lower Rate of Persistent Opioid Use After Total Joint Arthroplasty. <i>Arthroplasty Today</i> , 2022, 17, 145-149.	0.8	2
501	Marijuana Use in Organ Transplantation. <i>Psychiatry Update</i> , 2022, , 191-205.	0.1	0
502	Comparative Effects of Recreational and Medical Marijuana Laws on Drug Use among Adults and Adolescents. <i>Journal of Law and Economics</i> , 2022, 65, 515-554.	0.6	13
503	Endocannabinoid System and the Otolaryngologist. <i>Otolaryngologic Clinics of North America</i> , 2022, 55, 1101-1110.	0.5	2
504	Perspectives of Orthopedic Patients on Medical Cannabis: A Survey of More Than 2500 Patients. <i>Orthopedics</i> , 0, , 1-6.	0.5	0
505	Cannabis Use and Heart Transplantation: Disparities and Opportunities to Improve Outcomes. <i>Circulation: Heart Failure</i> , 0, , .	1.6	0
506	Recreational marijuana legalization and drug-related offenses in Washington State: an interrupted time series analysis with a combination of synthetic controls. <i>Journal of Experimental Criminology</i> , 0, , .	1.9	2

#	ARTICLE	IF	CITATIONS
507	Cannabis use and opioid relapse: An exploratory survival analysis of prospectively collected data. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
508	Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata. <i>Health Economics (United Kingdom)</i> , 0, , .	0.8	3
509	Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates. <i>American Journal of Perinatology</i> , 0, , .	0.6	1
510	Spillover Effects of the Opioid Epidemic on Consumer Finance. <i>Journal of Financial and Quantitative Analysis</i> , 0, , 1-43.	2.0	1
511	Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment. <i>JAMA Oncology</i> , 2023, 9, 206.	3.4	1
512	Co-use of cannabis and prescription opioids in adults in the USA: a population-based, cross-sectional analysis of the NHANES from 2009 to 2018. <i>Regional Anesthesia and Pain Medicine</i> , 0, , rapm-2022-103933.	1.1	2
513	Association of a Positive Drug Screening for Cannabis With Mortality and Hospital Visits Among Veterans Affairs Enrollees Prescribed Opioids. <i>JAMA Network Open</i> , 2022, 5, e2247201.	2.8	3
514	Alternatives to Prohibition and Legalization. , 2023, , 273-294.		0
515	The impact of recreational cannabis markets on motor vehicle accident, suicide, and opioid overdose fatalities. <i>Social Science and Medicine</i> , 2023, , 115680.	1.8	2
516	The Legalisation of Cannabis. <i>Advances in Business Strategy and Competitive Advantage Book Series</i> , 2023, , 215-230.	0.2	1
517	Marijuana legalization and opioid deaths. <i>Journal of Health Economics</i> , 2023, 88, 102728.	1.3	6
518	The Quebec Cannabis Registry: Investigating the Safety and Effectiveness of Medical Cannabis. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 1106-1116.	1.5	5
519	Clinical Research Evidence Supporting Administration and Dosing Recommendations of Medicinal Cannabis as Analgesic in Cancer Patients. <i>Journal of Clinical Medicine</i> , 2023, 12, 307.	1.0	3
520	How Demographic Factors Impact Attitudes Toward the Recreational Use of Cannabis. <i>Cureus</i> , 2023, , .	0.2	0
521	The association between cannabis use and risk of non-medical pain reliever misuse onset among young adults in a legal cannabis context. <i>Addictive Behaviors</i> , 2023, 143, 107711.	1.7	4
522	Marijuana as medicine. , 2023, , 349-358.		0
523	Trends of the Global Burden of Disease Attributable to Cannabis Use Disorder in 204 Countries and Territories, 1990â€“2019: Results from the Disease Burden Study 2019. <i>International Journal of Mental Health and Addiction</i> , 0, , .	4.4	5
524	The Public Health Effects of Legalizing Marijuana. <i>Journal of Economic Literature</i> , 2023, 61, 86-143.	4.5	10

#	ARTICLE	IF	CITATIONS
525	Implications of Cannabis Legalization on Substance-Related Benefits and Harms for People Who Use Opioids: A Canadian Perspective. Cannabis and Cannabinoid Research, 0, , .	1.5	0
526	Have recreational marijuana laws undermined public health progress on adult tobacco use?. Journal of Health Economics, 2023, 90, 102756.	1.3	2
527	The endocannabinoid system and breathing. Frontiers in Neuroscience, 0, 17, .	1.4	1
531	Endometriosis: Features and potential role of medicinal cannabis. , 2023, , 483-494.		0
534	Defining problematic use of medicinal cannabis: Theoretical and empirical considerations. , 2023, , 105-116.		0